Telix Pharmaceuticals Limited (TLX.AX) announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for TLX101-CDx, (Pixclara, 18F-floretyrosine or 18F-FET), an investigational PET agent for the characterization of progressive or recurrent glioma (brain cancer) from treatment related changes in both adult and pediatric patients.
Pixclara has been granted Orphan Drug and Fast Track designation by the FDA, which facilitates expedited review and closer consultation with the agency during the review process.
FET PET (Pixclara) is already included in international clinical practice guidelines for the imaging of gliomas, however there is currently no FDA-approved targeted amino acid PET agent for adult and pediatric brain cancer imaging commercially available in the U.S.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.